Search

Your search keyword '"Pautasso, Chiara"' showing total 6 results
Start Over Author "Pautasso, Chiara" Search Limiters Full Text
6 results on '"Pautasso, Chiara"'

1. Efficacy and Feasibility of Dose/Schedule-Adjusted Rd-R Vs. Continuous Rd in Elderly and Intermediate-Fit Newly Diagnosed Multiple Myeloma (NDMM) Patients: RV-MM-PI-0752 Phase III Randomized Study

Author

Larocca, Alessandra, primary, Salvini, Marco, additional, De Paoli, Lorenzo, additional, Cascavilla, Nicola, additional, Benevolo, Giulia, additional, Galli, Monica, additional, Montefusco, Vittorio, additional, Caravita di Toritto, Tommaso, additional, Baraldi, Anna, additional, Spada, Stefano, additional, Giuliani, Nicola, additional, Pautasso, Chiara, additional, Pulini, Stefano, additional, Ronconi, Sonia, additional, Pescosta, Norbert, additional, Liberati, Anna Marina, additional, Patriarca, Francesca, additional, Cellini, Claudia, additional, Tosi, Patrizia, additional, Offidani, Massimo, additional, Cavo, Michele, additional, Palumbo, Antonio, additional, Boccadoro, Mario, additional, and Bringhen, Sara, additional

Published
2018
Full Text
View/download PDF

2. Long Term Outcome of Lenalidomide-Dexamethasone (Rd) Vs Melphalan-Lenalidomide-Prednisone (MPR) Vs Cyclophosphamide-Prednisone-Lenalidomide (CPR) As Induction Followed By Lenalidomide-Prednisone (RP) Vs Lenalidomide (R) As Maintenance in a Community-Based Newly Diagnosed Myeloma Population: Updated Analysis of EMN01 Phase III Study

Author

Bringhen, Sara, primary, Offidani, Massimo, additional, Musto, Pellegrino, additional, Liberati, Anna Marina, additional, Benevolo, Giulia, additional, Cascavilla, Nicola, additional, Genuardi, Mariella, additional, Gaidano, Gianluca, additional, Zamagni, Donatella, additional, Ferrando, Paola, additional, Pizzolo, Giovanni, additional, Derudas, Daniele, additional, Gambella, Manuela, additional, Dominietto, Alida, additional, Annibali, Ombretta, additional, De Sabbata, Giovanni Maria, additional, Gabbas, Attilio, additional, Musolino, Caterina, additional, Pautasso, Chiara, additional, Zambello, Renato, additional, La Nasa, Giorgio, additional, Maracci, Laura, additional, Palumbo, Antonio, additional, Hájek, Roman, additional, and Boccadoro, Mario, additional

Published
2017
Full Text
View/download PDF

3. Prognostic Impact of Minimal Residual Disease By ASO-RQ-PCR in Multiple Myeloma: A Pooled Analysis of 2 Phase III Studies in Patients Treated with Lenalidomide after Front-Line Therapy

Author

Oliva, Stefania, primary, Gambella, Manuela, additional, Larocca, Alessandra, additional, Spada, Stefano, additional, Marzanati, Eleonora, additional, Mantoan, Barbara, additional, Grammatico, Sara, additional, Conticello, Concetta, additional, Gamberi, Barbara, additional, Offidani, Massimo, additional, Liberati, Anna Marina, additional, Pautasso, Chiara, additional, Omedé, Paola, additional, Palumbo, Antonio, additional, and Boccadoro, Mario, additional

Published
2016
Full Text
View/download PDF

4. Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis

Author

Oliva, Stefania, primary, Gambella, Manuela, additional, Gilestro, Milena, additional, Muccio, Vittorio Emanuele, additional, Gay, Francesca, additional, Drandi, Daniela, additional, Ferrero, Simone, additional, Passera, Roberto, additional, Pautasso, Chiara, additional, Bernardini, Annalisa, additional, Genuardi, Mariella, additional, Patriarca, Francesca, additional, Saraci, Elona, additional, Petrucci, Maria Teresa, additional, Pescosta, Norbert, additional, Liberati, Anna Marina, additional, Caravita, Tommaso, additional, Conticello, Concetta, additional, Rocci, Alberto, additional, Musto, Pellegrino, additional, Boccadoro, Mario, additional, Palumbo, Antonio, additional, and Omedè, Paola, additional

Published
2016
Full Text
View/download PDF

5. Overall Survival Benefit for Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance with Bortezomib-Thalidomide (VMPT-VT) Versus Bortezomib-Melphalan-Prednisone (VMP) in Newly Diagnosed Multiple Myeloma Patients

Author

Palumbo, Antonio, primary, Bringhen, Sara, additional, Rossi, Davide, additional, Cavalli, Maide, additional, Ria, Roberto, additional, Gentilini, Silvia, additional, Patriarca, Francesca, additional, Nozzoli, Chiara, additional, Levi, Anna, additional, Guglielmelli, Tommasina, additional, Benevolo, Giulia, additional, Vincelli, Donatella, additional, Baldini, Luca, additional, Morabito, Fortunato, additional, Grasso, Mariella, additional, Marasca, Roberto, additional, Rizzo, Manuela, additional, Pautasso, Chiara, additional, Falcone, Antonietta Pia, additional, Gottardi, Daniela, additional, Montefusco, Vittorio, additional, Musolino, Caterina, additional, Cangialosi, Clotilde, additional, Mansueto, Giovanna, additional, Liberati, Anna Marina, additional, Magarotto, Valeria, additional, Omedè, Paola, additional, Musto, Pellegrino, additional, Petrucci, Maria Teresa, additional, and Boccadoro, Mario, additional

Published
2012
Full Text
View/download PDF

6. Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis.

Author

Oliva S, Gambella M, Gilestro M, Muccio VE, Gay F, Drandi D, Ferrero S, Passera R, Pautasso C, Bernardini A, Genuardi M, Patriarca F, Saraci E, Petrucci MT, Pescosta N, Liberati AM, Caravita T, Conticello C, Rocci A, Musto P, Boccadoro M, Palumbo A, and Omedè P

Subjects
Antineoplastic Combined Chemotherapy Protocols therapeutic use, Consolidation Chemotherapy, Disease Progression, Female, Humans, Lenalidomide, Maintenance Chemotherapy, Male, Middle Aged, Multiple Myeloma genetics, Multiple Myeloma pathology, Neoplasm, Residual, Prospective Studies, Thalidomide administration & dosage, Thalidomide therapeutic use, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Biomarkers, Tumor genetics, Multiple Myeloma therapy, Thalidomide analogs & derivatives, Transplantation, Autologous methods
Abstract

We analyzed 50 patients who achieved at least a very good partial response in the RV-MM-EMN-441 study. Patients received consolidation with autologous stem-cell transplantation (ASCT) or cyclophosphamide-lenalidomide-dexamethasone (CRD), followed by Lenalidomide-based maintenance. We assessed minimal residual disease (MRD) by multi-parameter flow cytometry (MFC) and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction (ASO-RQ-PCR) after consolidation, after 3 and 6 courses of maintenance, and thereafter every 6 months until progression. By MFC analysis, 19/50 patients achieved complete response (CR) after consolidation, and 7 additional patients during maintenance. A molecular marker was identified in 25/50 patients, 4/25 achieved molecular-CR after consolidation, and 3 additional patients during maintenance. A lower MRD value by MFC was found in ASCT patients compared with CRD patients (p=0.0134). Tumor burden reduction was different in patients with high-risk vs standard-risk cytogenetics (3.4 vs 5.2, ln-MFC; 3 vs 6 ln-PCR, respectively) and in patients who relapsed vs those who did not (4 vs 5, ln-MFC; 4.4 vs 7.8 ln-PCR). MRD progression anticipated clinical relapse by a median of 9 months while biochemical relapse by a median of 4 months. MRD allows the identification of a low-risk group, independently of response, and a better characterization of the activity of treatments.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results